An?open-label phase II prospective clinical trial to?investigate safety, tolerability, maximum tolerated dose and anti-tumor?effect for SCO-101 in combination with?FOLFIRI?as?a safe and efficient treatment modality?in metastatic or advanced colorectal cancer (mCRC) patients with acquired?FOLFIRI?resistant cancer disease.

开始日期2022-01-21

申办/合作机构

Scandion Oncology A/S

NCT04652206 / Unknown status临床1/2期

An Open-label Phase Ib Prospective Clinical Trial to Investigate Safety, Tolerability and Maximum Tolerated Dose for SCO-101 in Combination With Gemcitabine and Nab-paclitaxel in Inoperable Pancreatic Cancer Patients.

An open-label dose escalating phase Ib study of SCO-101 in combination with gemcitabine and nab-paclitaxel. The primary objectives are to establish the safety profile and the MTD of SCO-101 when combined with gemcitabine and nab-paclitaxel. The starting dose of SCO-101 is 150 mg and the dose may be increased to a maximum of 350 mg.

开始日期2020-10-27

申办/合作机构

Scandion Oncology A/S

[+1]

NCT04247256 / Unknown status临床1/2期

An Open-label Phase II Prospective Clinical Trial to Investigate Safety, Tolerability, Maximum Tolerated Dose and Anti-tumor Effect for SCO-101 in Combination With FOLFIRI as a Safe and Efficient Treatment Modality in Metastatic or Advanced Colorectal Cancer (mCRC) Patients With Acquired FOLFIRI Resistant Cancer Disease.

This study evaluates the combination of SCO-101 to FOLFIRI for the treatment of metastatic colorectal cancer patients who have developed resistance to FOLFIRI treatment. The study is divided in two parts, where the first part evaluates the safety and toxicity of increasing doses of SCO-101 in combination with FOLFIRI at the same dose as the patient has previously developed resistance to. The second part of the study evaluates the safety and efficacy of the combination of FOLFIRI and SCO-101 at the dose level established in the first part.

开始日期2020-05-14

申办/合作机构

Scandion Oncology A/S

[+1]

100 项与 Endovion 相关的临床结果

登录后查看更多信息

100 项与 Endovion 相关的转化医学

登录后查看更多信息

100 项与 Endovion 相关的专利（医药）

登录后查看更多信息

项与 Endovion 相关的文献（医药）

2023-12-31·Virulence

LRRC8A promotes Glaesserella parasuis cytolethal distending toxin-induced p53-dependent apoptosis in NPTr cells

Article

作者: Mao, Weiting ; Wen, Siting ; Gu, Jiayun ; Cao, Qi ; Sun, Ju ; Wang, Huan ; Wang, Zhichao ; Xu, Xiaojuan ; Lin, Yan ; Cai, Xuwang ; Xu, Yindi

Glaesserella parasuis is an early colonizer of the swine upper respiratory tract and can break through the respiratory barrier for further invasion. However, the mechanisms underlying G. parasuis increases epithelial barrier permeability remain unclear. This study demonstrates that G. parasuis cytolethal distending toxin (CDT) induces p53-dependent apoptosis in new-born piglet tracheal (NPTr) cells. Moreover, we report for the first time that leucine-rich repeat-containing protein 8A (LRRC8A), an essential subunit of the volume-regulated anion channel (VRAC), involves in apoptosis of NPTr cells mediated by G. parasuis CDT. Pharmacological inhibition of VRAC with either PPQ-102 or NS3728 largely attenuated CDT-induced apoptosis in NPTr cells. Additionally, experiments with cells knocked down for LRRC8A using small interfering ribonucleic acid (siRNA) or knocked out LRRC8A using CRISPR/Cas9 technology showed a significant reduction in CDT-induced apoptosis. Conversely, re-expression of Sus scrofa LRRC8A in LRRC8A^-/- NPTr cells efficiently complemented the CDT-induced apoptosis. In summary, these findings suggest that LRRC8A is pivotal for G. parasuis CDT-induced apoptosis, providing novel insights into the mechanism of apoptosis caused by CDT.

2020-10-01·Basic & Clinical Pharmacology & Toxicology3区 · 医学

Four phase 1 trials to evaluate the safety and pharmacokinetic profile of single and repeated dosing of SCO‐101 in adult male and female volunteers

3区 · 医学

Article

作者: Bergmann, Troels K. ; Jacobsen, Thomas A. ; Stenvang, Jan ; Christophersen, Palle ; Brünner, Nils ; Roest, Nicklas L. ; Vestlev, Peter M. ; Stage, Tore B.

AbstractSCO‐101 (Endovion) was discontinued 20 years ago as a new drug under development against sickle cell anaemia. Data from the phase 1 studies remained unpublished. New data indicate that SCO‐101 might be efficacious as add‐on therapy in cancer. Thus, we report the results from the four phase 1 trials performed between 2001 and 2002. Adult volunteers received SCO‐101 or placebo in four independent trials. Adverse events were recorded, and SCO‐101 was determined for pharmacokinetic analysis. Ninety‐two volunteers completed the trials. The most remarkable adverse effect was a transient and dose‐dependent increase in unconjugated bilirubin. Plasma SCO‐101 elimination was approximately log linear, with apparent oral clearances of between 315 and 2103 mL/h for single doses, and between 121 and 2433 mL/h at steady state following oral administration. There was a marked decrease in clearance with increasing dose, and for repeated dose versus single dose. Tmax was greater, and Cmax and AUC∞ were lower in the fed state compared to the fasted state. Exposure was equivalent in males and females and for African Americans and Caucasians. In conclusion, SCO‐101 appears to be a safe drug with a predictable PK profile. Its efficacy as add‐on to standard anticancer drugs has yet to be defined.

2020-05-01·European Journal of Pharmaceutical Sciences2区 · 医学

Pharmacodynamic modelling reveals synergistic interaction between docetaxel and SCO-101 in a docetaxel-resistant triple negative breast cancer cell line

2区 · 医学

Article

作者: Stenvang, Jan ; Lund, Trine Meldgaard ; Nøhr-Nielsen, Asbjørn ; Brünner, Nils ; Bagger, Sofie Otzen

One of the primary barriers in treating cancer patients is the development of resistance to the available treatments. This is the case for treatment of triple negative breast cancer (TNBC) with docetaxel, which is part of the neoadjuvant treatment for TNBC. The novel compound SCO-101 is under investigation for its potential treatment effect in several types of drug resistant cancer. The aim of this study was to establish a pharmacodynamic model that captures the effect of docetaxel, SCO-101, and the combination on cell survival in docetaxel resistant MDA-MB-231 TNBC cells. Several combination models were compared and a recently published combination model, the general pharmacodynamic interaction model (GPDI), provided the best fit. The model allowed for description and quantification of the interaction between docetaxel and SCO-101 with respects to both maximal effect and potency. Based on this model, SCO-101 has a synergistic effect with docetaxel. This synergy is not present in the maximal effect, but the combination of SCO-101 and docetaxel showed an approximately 60% increase in potency compared to docetaxel alone. Furthermore, the predicted model surface for the combination provided key information regarding promising dose ratios and dose levels for further studies of the combination. Lastly, the study presents a use case for the GPDI model, which provides a way to quantify and interpret drug-drug interactions.

项与 Endovion 相关的新闻（医药）

2024-08-29

·scandiononcology.com

Scandion Oncology – Interim Report Q2 2024

Scandion Oncology (Scandion) today announces its Interim Report Q2 2024. The following is taken from the report. Francois Martelet, CEO: “With positive data and new financing, our top priority is now business development and partnering activities” Key Figures & Highlights Highlights during Q2 2024 On April 19, Scandion Oncology announced the intention, subject to authorizations by the annual general meeting of the Company on 6 May 2024, to carry out a Rights Issue with preferential rights for the Company’s existing shareholders. The Rights Issue of potentially SEK 60 million is secured up to SEK 30.6 million. On May 13, Scandion announced final data from the Phase Ib open-label PANTAX trial which confirms the good safety profile of SCO-101 and shows good signs of efficacy in hard-to-treat pancreatic cancer. On June 3, Scandion announced, that the company has entered into an agreement with Vator Securities AB regarding the service as a Certified Adviser. Vator Securities will be appointed Certified Adviser (CA) on September 1, 2024. On June 25, Scandion announced the outcome of the rights issue of units. The Rights Issue was subscribed to a total of approximately 50.3 percent. Through the Rights Issue, Scandion will initially receive approximately SEK 30.6 million before issue costs and in the event of exercise of warrants of series TO 2 and TO 3, in November 2024 and April 2025, respectively, the Company will receive additional proceeds. Highlights after the end of the period On July 1, Scandion board member Michel Ducreux stepped down due to ESMO scientific society’s guidelines prohibiting such board positions. He joined the advisory board. On August 16, Scandion Oncology achieved Maximum Tolerated Dose (MTD) for CORIST part 3. The established MTD for a 4-Days schedule of SCO-101 in combination with FOLFIRI was found to be 250 mg daily SCO-101, 50% irinotecan and 100% Leucovorin and 5-FU. On August 19, Scandion announced that the top priority following the very encouraging part 3 CORIST data is business development and partnering activities. As part of these efforts, Scandion is working together with Back Bay Life Science Advisors LLC, a prominent life sciences investment banking firm, to explore and evaluate actionable strategic and financial alternatives. The Interim Report Q2 2024 is available on the Company's website: www.scandiononcology.com. Audiocast today, August 29 at 11:00 am CET Today at 11:00, Scandion Oncology’s executive management will host a webcast and conference call presenting the results and a company update. At the end of the presentation there will be a Q&A session. Access to the event can be obtained as follows: LIVE access today Thursday, August 29, 2024, at 11:00 CET: https://financialhearings.com/event/48942 REPLAY access Webcast replay will be available at www.scandiononcology.com in the Investors section and at www.financialhearings.com For further information please contact: Johnny Stilou, CFO Phone: +45 2960 3532 E-mail: jos@scandiononcology.com The information was provided by the contact person above for publication on August 29, 2024, at 07.00 CET. About Scandion Oncology Scandion Oncology (Scandion) is a clinical-stage biotech company using an innovative drug efflux pump inhibition technique with biomodulation capabilities on ABCG2 and UGT1A1 targets to revert drug resistance. Drug resistance remains a massive problem in cancer treatment and in the development of new medicines. Scandion’s lead compound SCO-101 is currently studying metastatic colorectal cancer (mCRC) in its Phase 2 CORIST trial, while the PANTAX Phase 1 program is developing SCO-101 for pancreatic cancer. Scandion is based in Copenhagen and is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL). Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market.

临床1期临床2期高管变更

2024-08-19

·scandiononcology.com

Scandion Oncology strengthens partnering outreach

Scandion Oncology (Scandion), an innovative drug efflux pump inhibition company using biomodulation capabilities to revert drug resistance, today announced that the top priority following the very encouraging part 3 CORIST data is business development and partnering activities. As part of these efforts, Scandion is working together with Back Bay Life Science Advisors LLC, a prominent life sciences investment banking firm, to explore and evaluate actionable strategic and financial alternatives. This decision reflects the company’s commitment to both the ongoing development of SCO-101 and maximizing shareholder value. Strategic alternatives include partnerships, divesting certain assets, and exploring a potential sale of the company. “The clinical data generated by Scandion’s SCO-101 throughout CORIST 1 to 3 certainly demonstrate the potential of the molecule to significantly reduce chemotherapy drug resistance due to its unique mechanism of action,” said Francois Martelet, CEO of Scandion Oncology. “While focusing on business development and partnering activities we will work with our clinical advisors on the best step forward to ensure SCO-101 reaches its potential in the light of current standard of care.” For further information please contact: Johnny Stilou, CFO Phone: +45 2960 3532 E-mail: jos@scandiononcology.com The information was provided by the contact person above for publication on August 19, 2024, at 07.00 CET. About Scandion Oncology Scandion Oncology (Scandion) is a clinical-stage biotech company using an innovative drug efflux pump inhibition technique with biomodulation capabilities on ABCG2 and UGT1A1 targets to revert drug resistance. Drug resistance remains a massive problem in cancer treatment and in the development of new medicines. Scandion’s lead compound SCO-101 is currently studying metastatic colorectal cancer (mCRC) in its Phase 2 CORIST trial, while the PANTAX Phase 1 program is developing SCO-101 for pancreatic cancer. Scandion is based in Copenhagen and is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL). Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market.

临床2期临床1期

2024-08-16

·scandiononcology

Scandion Oncology achieves Maximum Tolerated Dose for CORIST part 3

Scandion Oncology (Scandion), an innovative drug efflux pump inhibition company using biomodulation capabilities to revert drug resistance, today announced topline data for the CORIST part 3 continuation trial and that the company established the maximum tolerated dose (MTD) of SCO-101 in combination with the chemotherapy FOLFIRI in colorectal cancer patients. The established MTD for a 4-Days schedule of SCO-101 in combination with FOLFIRI was found to be 250 mg daily SCO-101, 50% irinotecan and 100% Leucovorin and 5-FU. “We are pleased to have reached the primary endpoint of this continuation trial, establishing the MTD of SCO-101 in combination with FOLFIRI,” said Lars Damstrup, CMO of Scandion Oncology. “We now have the recommended dose that we may use in the next steps of the development of SCO-101.” The continuation study of CORIST part 3 included 3 patients. The dose of SCO-101 was the same as in the previous cohort, i.e., 250 mg per day for four days. Folinic acid and 5-FU were administered as per standard of care. The dose of irinotecan was increased from 50% to 65% of the normal standard dose. Of the 3 patients, 2 experienced a dose-limiting toxicity of neutropenia, which was expected based on previous data. No new safety signals were detected. Final data in the CORIST part 3 continuation trial is expected in the first half of 2025. For further information please contact: Johnny Stilou, CFO Phone: +45 2960 3532 E-mail: jos@scandiononcology.com This information is information that Scandion Oncology A/S is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact person set out above on August 16, 2024, at 07.00 CET. About Scandion Oncology Scandion Oncology (Scandion) is a clinical-stage biotech company using an innovative drug efflux pump inhibition technique with biomodulation capabilities on ABCG2 and UGT1A1 targets to revert drug resistance. Drug resistance remains a massive problem in cancer treatment and in the development of new medicines. Scandion’s lead compound SCO-101 is currently studying metastatic colorectal cancer (mCRC) in its Phase 2 CORIST trial, while the PANTAX Phase 1 program is developing SCO-101 for pancreatic cancer. Scandion is based in Copenhagen and is listed on Nasdaq First North Growth Market Sweden (ticker: SCOL). Västra Hamnen Corporate Finance is the Company's certified advisor on Nasdaq First North Growth Market. This information is information that Scandion Oncology is obliged to make public pursuant to the EU Market Abuse Regulation. The information was submitted for publication, through the agency of the contact persons set out above, at 2024-08-16 07:00 CEST.

临床结果临床1期临床2期

100 项与 Endovion 相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB05835

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
不能切除性胰腺癌	临床1期	丹麦	Scandion Oncology A/S	2020-10-27
不能切除性胰腺癌	临床1期	德国	Scandion Oncology A/S	2020-10-27
转移性结直肠癌	临床1期	德国	Scandion Oncology A/S	2020-05-14
转移性结直肠癌	临床1期	西班牙	Scandion Oncology A/S	2020-05-14
局部晚期胰腺腺癌	临床前	德国	Scandion Oncology A/S	2020-10-27
局部晚期胰腺腺癌	临床前	丹麦	Scandion Oncology A/S	2020-10-27
转移性胰腺腺癌	临床前	德国	Scandion Oncology A/S	2020-10-27
转移性胰腺腺癌	临床前	丹麦	Scandion Oncology A/S	2020-10-27
胰腺癌	临床前	丹麦	Scandion Oncology A/S	2020-10-27
镰状细胞血症	药物发现	美国	Saniona AB	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04652206 (ESMO2023) 人工标引	临床1期	胰腺癌	22	SCO-101+gemcitabine + nab-paclitaxel	(醖醖願願蓋顧積鏇醖醖) = 壓夢顧築積窪廠蓋鏇淵醖糧構餘廠醖糧齋廠憲 (遞鹽繭鑰範願鹹糧蓋繭 )	积极	2023-10-23
				SCO-101+gemcitabine + nab-paclitaxel	(獵築積鏇選淵鏇廠鑰齋) = 築餘觸窪壓餘壓襯憲製齋範顧醖觸觸醖簾膚艱 (鑰鏇遞製願願餘範簾獵 )